Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site
Nichi-Iko Pharmaceutical Co., Ltd. ("Nichi-Iko") and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia"). Financial terms of the transaction have not been disclosed.
To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.
